Shanghai Junshi Biosciences Co Ltd
Company Profile
Business description
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
Contact
No. 987 Cai Lun Road
Level 4, China (Shanghai) Pilot Free Trade Zone
Shanghai
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2,903
Stocks News & Analysis
stocks
Margins have bottomed for ASX listed consumer goods company
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,988.30 | 61.40 | -0.68% |
| CAC 40 | 8,365.46 | 34.65 | -0.41% |
| DAX 40 | 24,952.76 | 186.93 | -0.74% |
| Dow JONES (US) | 51,758.95 | 46.24 | 0.09% |
| FTSE 100 | 10,455.87 | 18.02 | 0.17% |
| HKSE | 23,336.28 | 432.24 | -1.82% |
| NASDAQ | 25,760.44 | 406.16 | -1.55% |
| Nikkei 225 | 69,788.38 | 2,565.58 | -3.55% |
| NZX 50 Index | 13,435.77 | 10.28 | -0.08% |
| S&P 500 | 7,396.75 | 76.04 | -1.02% |
| S&P/ASX 200 | 8,787.00 | 48.10 | -0.54% |
| SSE Composite Index | 4,106.25 | 56.85 | -1.37% |